Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients. Issue 1 (January 2018)

• Record Type: Journal Article
• Authors: Hu, Xiaolei; Chen, Fengling
• Is Part Of: Endocrine connections. Volume 7:Issue 1(2018)
• Page Start: R47
• Page End: R55
• Publication Date: 2018-01
• Subjects: insulin antibodies -- exogenous insulin antibody syndrome -- diabetes -- hypoglycaemia -- hyperglycaemia; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EC-17-0309
• Languages: English
• ISSNs: 2049-3614

Abstract

Abstract : Insulin has been used for diabetes therapy and has achieved significant therapeutic effect. In recent years, the use of purified and recombinant human insulin preparations has markedly reduced, but not completely suppressed, the incidence of insulin antibodies (IAs). IAs induced by exogenous insulin in diabetic patients is associated with clinical events, which is named exogenous insulin antibody syndrome (EIAS). The present review is based on our research and summarizes the characterization of IAs, the factors affecting IA development, the clinical significance of IAs and the treatments for EIAS.